Cargando…

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies

We reviewed the literature (January 2010–June 2021) on the effectiveness of debulking strategies before venetoclax initiation in patients with chronic lymphocytic leukemia to reduce tumor burden, downgrade tumor lysis syndrome (TLS) risk, and avoid hospitalization. Low TLS incidence and reduced TLS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharman, Jeffrey P., Biondo, Juliana M. L., Boyer, Michelle, Fischer, Kirsten, Hallek, Michael, Jiang, Dingfeng, Kater, Arnon P., Porro Lurà, Michele, Wierda, William G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175963/ https://www.ncbi.nlm.nih.gov/pubmed/35846043 http://dx.doi.org/10.1002/jha2.427

Ejemplares similares

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022)

The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study
por: Mato, Anthony R., et al.
Publicado: (2020)

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2021)

Tumor Lysis Syndrome Caused by Unrecognized Richter’s Transformation of Chronic Lymphocytic Leukemia: Treatment With Venetoclax for Suspected Disease Progression
por: Chango Azanza, Juan Jose, et al.
Publicado: (2020)

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
por: Yi, Xue, et al.
Publicado: (2022)

Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts
por: Barr, Paul M., et al.
Publicado: (2022)

Practical management of tumour lysis syndrome in venetoclax‐treated patients with chronic lymphocytic leukaemia
por: Gribben, John G.
Publicado: (2019)

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
por: Herling, Carmen D., et al.
Publicado: (2018)

Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?
por: Haselager, Marco V., et al.
Publicado: (2020)

Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial
por: Samineni, Divya, et al.
Publicado: (2022)

Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?
por: de Weerdt, Iris, et al.
Publicado: (2019)

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
por: Thus, Yvonne J., et al.
Publicado: (2022)

Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia
por: Hofland, Tom, et al.
Publicado: (2019)

T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective
por: Peters, Fleur S., et al.
Publicado: (2021)

Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk
por: van Attekum, Martijn HA, et al.
Publicado: (2017)

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
por: Schieber, Michael, et al.
Publicado: (2019)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

P634: EARLY-STAGE MEASURABLE RESIDUAL DISEASE DYNAMICS AND IGHV REPERTOIRE RECONSTITUTION DURING VENETOCLAX AND OBINUTUZUMAB TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Hengeveld, Paul, et al.
Publicado: (2023)

Venetoclax with Azacitidine Induced Tumor Lysis Syndrome in an Elderly Patient with Acute Myeloid Leukemia: A Case Report
por: Kim, Mihee, et al.
Publicado: (2021)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
por: Handunnetti, Sasanka, et al.
Publicado: (2021)

COVID-19 among fit patients with CLL treated with venetoclax-based combinations
por: Fürstenau, Moritz, et al.
Publicado: (2020)

Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies
por: Gopalakrishnan, Sathej, et al.
Publicado: (2023)

Successful Retreatment With Venetoclax in a Patient With Chronic Lymphocytic Leukemia
por: Jackson, Ross A., et al.
Publicado: (2022)

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
por: Muhowski, Elizabeth M., et al.
Publicado: (2022)

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia
por: Hengeveld, P. J., et al.
Publicado: (2023)

Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells
por: Chen, Rong, et al.
Publicado: (2022)

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
por: Al-Sawaf, Othman, et al.
Publicado: (2017)

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
por: Kater, Arnon, et al.
Publicado: (2023)

Radiation-Induced Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia
por: Alkan, Ali, et al.
Publicado: (2016)

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
por: Martens, Anne W J, et al.
Publicado: (2020)

Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
por: Waggoner, Matthew, et al.
Publicado: (2022)

Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects
por: Tariq, Saba, et al.
Publicado: (2020)

Venetoclax: a real game changer in treatment of chronic lymphocytic leukemia
por: Molica, Stefano
Publicado: (2020)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia
por: Aumann, Shlomzion, et al.
Publicado: (2022)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up
por: Shahswar, Rabia, et al.
Publicado: (2020)

Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features
por: van der Straten, Lina, et al.
Publicado: (2021)

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
por: Kater, Arnon P., et al.
Publicado: (2020)

S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL
por: Urban, Aleksandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jg78be1ommcgu2fgrd3vjompud